In patients with atrial fibrillation, the large 4 trials, WOEST, PIONEER AF, RE-DUAL PCI, and AUGUSTUS trials and their network meta-analysis demonstrate that the treatment with DOAC and P2Y12 inhibitor could reduce bleeding risk without an increased risk of ischemic events up to 1 year after PCI, compared to vitamin K-antagonist plus DAPT (i.e., triple therapy) [191–195]. The gene discussed is P2RY12; the disease is atrial fibrillation.